Immunovaccine Inc. (IMV.V) Signs Research Agreement with Vaxil BioTherapeutics
Yesterday, representatives from Immunovaccine Inc. announced that the company has signed a collaborative research agreement with Vaxil BioTherapeutics. The research agreement aims to explore the efficacy of Vaxil's cancer antigens in its Immunovaccine's DepoVax™ vaccine enhancement platform. Headquartered in Israel, Vaxil BioTherapeutics is a pioneer in T-cell synthetic vaccines development for therapeutic and prophylactic use. The company has identified a large number of vaccine candidates in the fields of cancer and infectious diseases using its proprietary technology VaxHit™. In other news, ImMucin™, the company’s lead product, has received regulatory permission to start Phase I/II clinical trials in Multiple Myeloma patients,…